| Literature DB >> 36117784 |
Ehssan H Moglad1,2, Hisham N Altayb3.
Abstract
Methicillin-resistant Staphylococcus spp. (MRSS) are causing numerous forms of illness in humans ranging from mild to fatal infections. We need to investigate the resistant pattern for different clinical isolates to control the resistance phenomena. This study was designed to provide the resistance pattern of isolated Staphylococcus spp. from various clinical samples in Khartoum State and to elucidate the frequencies of Multidrug-resistant (MDR), Extensively drug-resistant (XDR) and pan-drug resistant (PDR). Two hundred and ten bacterial isolates were from different sources (catheter tip, sputum, vaginal swab, urine, tracheal aspirate, blood, pus, nasal swab, stool, throat swab, pleural fluid, and ear swab). Isolates were identified based on their morphological characters and biochemical reaction. Antibiotics susceptibility screening was performed using twenty-three antibiotics from eighteen classes against all isolated Staphylococcus spp. following the Clinical and Laboratory Standards Institute (CLSI) guideline. The result revealed that out of 63 Gram-positive isolated bacteria, 52 (82.5%) were Staphylococcus spp. with a high incidence of S. aureus 37(71.2%). Out of all Staphylococcus spp., 38 (73.1%) were Methicillin-resistant (MR). The prevalence of MDR was higher in S. aureus (89.2%) than in S. epidermidis (75%). All Staphylococcus spp. displayed resistance to ampicillin and penicillin, while all S. aureus were sensitive to daptomycin and fosfomycin. One isolate was XDR possible PDR, while no PDR was reported in all isolated bacteria. This study provided evidence for the antimicrobial-resistant (AMR) burden in Sudan and highlighted the need for a practical and functional stewardship program to reduce the unreasonable costs of antibiotics.Entities:
Keywords: AMR, Antimicrobial-resistant; ATCC, American Type Culture Collection; Antibiotics profile; CLSI, Clinical and Laboratory Standards Institute; Extensive drug-resistant; Khartoum-Sudan; MDR, Multidrug-resistant; MRSA, methicillin-resistant S. aureus; MRSS, Methicillin-resistant Staphylococcus spp; Multidrug-resistant; PDR, Pandrug-resistant; S. aureus; XRD, Extensively drug-resistant; βeta-lactamase
Year: 2022 PMID: 36117784 PMCID: PMC9478920 DOI: 10.1016/j.sjbs.2022.103432
Source DB: PubMed Journal: Saudi J Biol Sci ISSN: 2213-7106 Impact factor: 4.052
Prevalence and association between Gram-positive bacteria and sources of samples.
| Gram-positive bacteria | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | 1 | 2 | 2 | 1 | 3 | 13 | 0 | 15 | 0 | 37 | |
| % | 1.6 | 3.2 | 3.2 | 1.6 | 4.8 | 20.6 | 0.0 | 23.8 | 0.0 | 58.7 | |
| N | 0 | 1 | 0 | 4 | 0 | 2 | 0 | 0 | 1 | 8 | |
| % | 0.0 | 1.6 | 0.0 | 6.3 | 0.0 | 3.2 | 0.0 | 0.0 | 1.6 | 12.7 | |
| N | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | |
| % | 0.0 | 3.2 | 0.0 | 1.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.8 | |
| N | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | |
| % | 0.0 | 0.0 | 0.0 | 0.0 | 1.6 | 0.0 | 0.0 | 0.0 | 0.0 | 1.6 | |
| N | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | |
| % | 0.0 | 0.0 | 0.0 | 1.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.6 | |
| N | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | |
| % | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.6 | 0.0 | 0.0 | 0.0 | 1.6 | |
| N | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | |
| % | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.6 | 0.0 | 0.0 | 0.0 | 1.6 | |
| N | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | |
| N | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 3 | 0 | 7 | |
| Total | N | 1 | 8 | 4 | 9 | 4 | 17 | 1 | 18 | 1 | 63 |
| % | 1.6 | 12.7 | 6.3 | 14.3 | 6.3 | 27.0 | 1.6 | 28.6 | 1.6 | 100.0 | |
| 0.001 | |||||||||||
Prevalence of MDR and MRSS among isolated Staphylococcus spp.
| Bacteria | Number and percentage of isolates | |||||
|---|---|---|---|---|---|---|
| N | 37 | 33 | 4 | 25 | 12 | |
| % | 100 | 89.2 | 10.8 | 67.6 | 32.4 | |
| N | 8 | 6 | 2 | 7 | 1 | |
| % | 100 | 75 | 25 | 87.5 | 12.5 | |
| N | 3 | 3 | 0 | 3 | 0 | |
| % | 100 | 100 | 0 | 100 | 0 | |
| N | 1 | 1 | 0 | 1 | 0 | |
| % | 100 | 100 | 0 | 100 | 0 | |
| N | 1 | 1 | 0 | 1 | 0 | |
| % | 100 | 100 | 0 | 100 | 0 | |
| N | 1 | 1 | 0 | 1 | 0 | |
| % | 100 | 100 | 0 | 100 | 0 | |
| N | 1 | 1 | 0 | 0 | 1 | |
| % | 100 | 100 | 0 | 0 | 100 | |
| 0.001 | 0.001 | |||||
Key: MDR: multidrug-resistant bacteria, MRSS: Methicillin-resistant Staphylococcus spp.
Antimicrobial resistance pattern of Staphylococcus spp. isolated from different clinical samples.
| Name | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | 14 | 13 | 12 | 22 | 15 | 0 | 37 | 0 | 9 | 2 | 11 | 26 | |
| % | 37.8 | 35.1 | 32.4 | 59.5 | 40.5 | 0.0 | 100 | 0.0 | 24.3 | 5.4 | 29.7 | 70.3 | |
| N | 4 | 4 | 2 | 5 | 5 | 0 | 8 | 1 | 3 | 1 | 3 | 7 | |
| % | 50 | 50 | 25 | 62.5 | 62.5 | 0.0 | 100 | 12.5 | 37.5 | 12.5 | 37.5 | 87.5 | |
| N | 1 | 1 | 0 | 1 | 1 | 0 | 3 | 0 | 1 | 0 | 1 | 3 | |
| % | 33.3 | 33.3 | 0.0 | 33.3 | 33.3 | 0.0 | 100 | 0.0 | 33.3 | 0.0 | 33.3 | 100 | |
| N | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| N | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | |
| % | 0.0 | 0.0 | 0.0 | 100 | 100 | 0.0 | 100 | 0.0 | 0.0 | 0.0 | 0.0 | 100 | |
| N | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | |
| % | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 100 | 0.0 | 100 | 0.0 | 100 | 100 | |
| N | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| % | 0.0 | 0.0 | 0.0 | 100 | 0.0 | 0.0 | 100 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Key: N: Number of resistant bacteria, CIP: Ciprofloxacin, MXF: Moxifloxacin, LVX: Levofloxacin, AZM: Azithromycin, E: Erythromycin, DAP: Daptomycin, AM: Ampicillin, FOS: Fosfomycin, CM: Clindamycin, FA: Fusic acid, GM: Gentamicin, IPM: Imipenem.
P = Pencillin, OX = Oxacillin, VA = Vancomycin, TEC = Teicoplanin, SYN = Synercid, SXT = Trimethoprim-sulfamethoxazole, TE = Tetracycline, RA = Rifampin, LZD = Linezolid, AMC = Amoxicillin-clavulanate, MUP = Mupirocin, NT = not tested.